Skip to main content
. 2012 Feb 16;106(6):1039–1044. doi: 10.1038/bjc.2012.47

Figure 2.

Figure 2

Progression-free survival (A) and OS (B) times based on baseline expression of pS6Ser240/4 (immunohistochemistry score <2 vs ⩾2).